Biotechnology
JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the c...
2024-01-02 20:15
2489
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...
2024-01-02 20:06
2665
Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that Dr.Hai Wu, President of R&D of Mabwell, will attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase in San Francisco, United State...
2024-01-02 17:15
1768
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Jan. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...
2024-01-02 08:00
9167
TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data
* The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. * Data read-outs from a Phase 2 trial of merigolix in endometriosis and a Phase1b trial of TU2218 in solid tumors are expected in the first half of 2024 BOSTON and SEONGNAM, South Korea, Dec. 29, 2...
2023-12-29 21:00
2480
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive...
2023-12-29 12:33
2590
HANSIZHUANG Sets Sail in Indonesia Market
* The 1st China anti-PD-1 monoclonal antibody successfully approved in Southeast Asia - * The 1st overseas approval of HANSIZHUANG, highlighting another major milestone of Henlius' global strategy after HANQUYOU - * Along with KGbio and other partners to develop and launch HANSIZHUANG in ov...
2023-12-28 21:51
3461
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
2023-12-28 15:45
2253
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
ROCKVILLE, Md. and SUZHOU, China, Dec. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-12-28 08:00
3761
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA): one is BA1105, an innovat...
2023-12-27 20:50
3169
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024
CBL-514 Phase 2 Study Results for local fat reduction demonstrated 85.7% and 76.2% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after receiving CBL-514 treatment(s). NEW TAIPEI CITY, Dec. 26, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Cal...
2023-12-27 11:49
1773
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs
SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney ...
2023-12-26 17:26
1970
Panlin Capital Announces Second Closing for its Healthcare Venture Capital Fund; Has Raised a Total of RMB 1.5 Billion in the Last Two Years
SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Recently, Panlin Capital announced that Hangzhou Panlin Xukang Fund, a venture capital fund focusing on innovative biopharmaceuticals, innovative medical device and biotechnology, has completed its second closing. This is the first fund that Panlin Capital ...
2023-12-26 12:59
2879
PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development
NANJING, China, Dec. 25, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced the successful attainment of Energy Management System Certification...
2023-12-26 11:00
2065
Harbin City Pushes for Breakthroughs in Full Revitalization of Northeast China
HARBIN, China, Dec. 25, 2023 /PRNewswire/ -- Harbin, capital of Heilongjiang Province, has strived to build itself into a city of innovation, by sticking to reform and innovation and stimulating endogenous strength to push for breakthroughs in the full revitalization of northeastChina. The Harbi...
2023-12-25 20:42
2185
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
NANJING, China, Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. However, the transition from basic research to clinical commercialization presents formidable challenge...
2023-12-25 10:15
2131
GenSci Launches Global Innovation Hub in Shanghai
The Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ -- Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), h...
2023-12-23 15:41
3045
Davos Communications Awards - BGI Genomics Inclusive Instagram Strategy Wins Gold Recognition
HONG KONG, Dec. 22, 2023 /PRNewswire/ -- BGI Genomics, the world's leading provider of integrated solutions for precision medicine, is pleased to announce winning Instagram Campaign (Gold) recognition at the Davos Communications Awards held onDecember 12, 2023. Organized by the World Communicati...
2023-12-22 08:19
2980
Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore
First drug to show both clinical symptomatic efficacy for five typical
Omicron-related symptoms and antiviral efficacy
SINGAPORE, Dec. 22, 2023 /PRNewswire/ -- Singapore-headquartered Juniper
Therapeutix
2023-12-22 07:00
2689
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma
NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420), ...
2023-12-21 21:45
1448
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
